Neutrophil CD64 for monitoring the activity of nontuberculous mycobacteria infection in patients with rheumatoid arthritis

References

• Leino L, Sorvajärvi K, Katajisto J, Laine M, Lilius EM, Pelliniemi TT, et al. Febrile infection changes the expression of IgG Fc receptors and complement receptors in human neutrophils in vivo. Clin Exp Immunol. 1997;107(1):37–43.
   Google Scholar
• Fjaertoft G, Hakansson L, Ewald U, Foucard T, Venge P. Neutrophils from term and preterm newborn infants express the high affinity Fc gamma-receptor I (CD64) during bacterialinfections. Pediatr Res. 1999;45(6):871–6.
   Google Scholar
• Ng PC, Li K, Wong RP, Chui KM, Wong E, Fok TF. Neutrophil CD64 expression: a sensitive diagnostic marker for late-onset nosocomial infection in very low birthweight infants. Pediatr Res. 2002;51(3):296–303.
   Google Scholar
• Layseca-Espinosa E, Pérez-González LF, Torres-Montes A, Baranda L, de la Fuente H, Rosenstein Y, González-Amaro R. Expression of CD64 as a potential marker of neonatal sepsis. Pediatr Allergy Immunol. 2002;13(5):319–27.
   Google Scholar
• Buckle AM, Hogg N. The effect of IFN-gamma and colony-stimulating factors on the expression of neutrophil cell membrane receptors. J Immunol. 1989;143(7):2295–301.
   Google Scholar
• Kerst JM, de Haas M, van der Schoot CE, Slaper-Cortenbach IC, Kleijer M, von dem Borne AE, van Oers RH. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood. 1993;82(11):3265–72.
   Google Scholar
• Matsui T, Ohsumi K, Ozawa N, Shimada K, Sumitomo S, Shimane K, et al. CD64 on neutrophils is a sensitive and specific marker for detection of infection in patients with rheumatoid arthritis. J Rheumatol. 2006;33(12):2416–24.
   Google Scholar
• Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–94.
   Google Scholar
• Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, Fukuda J. Cause of death in 81autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1):33–6.
   Google Scholar
• Takayanagi N, Tsuchiya Y, Tokunaga D, Miyahara Y, Yamaguchi S, Saito H, et al. Pulmonary infections in patients with rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2007;45(6):465–73.
   Google Scholar
• Morimoto K, Iwai K, Ohmori M, Okumura M, Yoshiyama T, Yoshimori K, et al. Nontuberculous mycobacteriosis mortality in Japan. Kekkaku 2011;86(5):547–52.
   Google Scholar
• Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185(8):881–6.
   Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50(2):372–9.
   Google Scholar
• Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis. 2009;15(10):1556–61.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The AmericanRheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
   PubMed Web of Science ®Google Scholar
• Winthrop KL. Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view. Future Microbiol. 2010; 5(3):343–5.
   Google Scholar
• Mori S, Tokuda H, Sakai F, Johkoh T, Mimori A, Nishimoto N, et al.; NTM-BIORA (NTM infection in Biologic-treated RA patients) Study Investigators. Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan. Mod Rheumatol. 2012;22(5):727–37.
   Google Scholar
• Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8.
   Google Scholar
• Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processe. Ann Rheum Dis. 2003;62(4):337–40.
   Google Scholar
• Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J. 1999;18(10):875–81.
   Google Scholar
• Schwarz S, Bertram M, Schwab S, Andrassy K, Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med. 2000;28(6):1828–32.
   PubMedGoogle Scholar
• Ugajin M, Miwa S, Shirai M, Ohba H, Eifuku T, Nakamura H, et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J. 2011;37(2):371–5.
   Google Scholar
• Naderi M, Hashemi M, Kouhpayeh H, Ahmadi R. The status of serum procalcitonin in pulmonary tuberculosis and nontuberculosis pulmonary disease. J Pak Med Assoc.2009;59(9):647–8.
   Google Scholar
• Shu CC, Lee LN, Wu MF, Lee CH, Wang JT, Wang JY, et al.; TAMI Group. Use of soluble triggering receptor expressed on myeloid cells-1 in non-tuberculous mycobacterial lung disease. Int J Tuberc Lung Dis. 2011;15(10):1415–20.
   Google Scholar
• Alemán M, Beigier-Bompadre M, Borghetti C, de la Barrera S, Abbate E, Isturiz M, Sasiain MC. Activation of peripheral blood neutrophils from patients with active advanced tuberculosis. Clin Immunol. 2001;100(1):87–95.
   Google Scholar